Human Cancer Markers

1. Front Matter

   Pages i-xx

   PDF

2. Monoclonal Antibodies to Human Tumor Antigens

   • William C. Raschke

   Pages 1-32

3. Cell Surface Antigens on Normal and Neoplastic Human Lymphoid Cells

   • Robert Fox, Stephen Baird, Patrick Kung, Ron Levy, Ivor Royston

   Pages 33-68

4. An Immunochemical Approach to the Isolation of Human Melanoma-Associated Antigens

   • D. R. Galloway, R. A. Reisfeld

   Pages 69-88

5. Skin Tumor Markers

   • Jean-Claude Bystryn

   Pages 89-104

6. Gastrointestinal Cancer Markers

   • Hans O. Sjögren, Britta Wahren

   Pages 105-132

7. Hepatocellular Carcinoma Markers

   • Stewart Sell

   Pages 133-164

8. Pancreatic Tumor Markers

   • John R. Hobbs

   Pages 165-177

9. Prostate Cancer Markers

   • T. Ming Chu, Ming C. Wang, Ching-li Lee, Carl S. Killian, Manabu Kuriyama, Lawrence D. Papsidero et al.

   Pages 179-190

10. Breast Cancer Markers

    • Thomas S. Edgington, Robert M. Nakamura

    Pages 191-232

11. Ovarian and Uterine Cancer Markers

    • Markku Seppälä

    Pages 233-257

12. Testicular Cancer Markers

    • Paul H. Lange

    Pages 259-273

13. Placental Proteins as Tumor Markers

    • Torgny Stigbrand, Eva Engvall

    Pages 275-301

14. Bladder and Renal Tumor Markers

    • Britta Wahren, Peter Perlmann

    Pages 303-319

15. Endocrine Markers of Cancer

    • Geoffrey Mendelsohn, Stephen B. Baylin

    Pages 321-358

16. Lung Cancer Markers

    • K. Robert McIntire

    Pages 359-380

17. Central Nervous System Tumor Markers

    • Trevor R. Jones, Darell D. Bigner

    Pages 381-422

18. Back Matter

    Pages 423-428

    PDF

The ability to diagnose cancer by simple measurement of a serum or tissue' 'marker" has been a goal of medical science for many years. There is ample evidence that tumor cells are different from normal cells and pro­ duce substances that can be detected by currently available immuno­ chemical or biochemical methods. These "cancer markers" may be se­ creted proteins, enzymes, hormones, fetal serum components, monoclonal immunoglobulins, cell surface components, or cytoplasmic constituents. The purpose of this book is to present the current status of our knowledge of such cancer markers. The first tumor marker identified by laboratory means was Bence­ Jones protein. In a series of lectures delivered to the Royal College of Phy­ sicians in London in 1846, Dr. H. Bence Jones described studies on a urine sample sent to him with the following note: "Dear Dr. Jones-The tube contains urine of very high specific gravity. When boiled it becomes slightly opaque . . . . etc. " Dr. Jones found that heating of the urine after addition of nitric acid resulted in formation of a heavy precipitate; acid ad­ dition may have been required to bring the urine to pH 4-6 at which Bence Jones proteins are more likely to precipitate when heated. This urinary pre­ cipitate was associated with a bone disease termed "mollities ossium. " [H. Bence Jones, Papers on Chemical Pathology, Lecture III. Lancet 2, 269-274 (1847)].

• CT
• Staging
• cancer
• carcinoma
• cell
• computed tomography (CT)
• gastric cancer
• hormones
• leukemia
• lymphocytes
• lymphoma
• melanoma
• pathology
• tissue
• tumor

• University of California, San Diego, USA

  Stewart Sell

• Karolinska Hospital, Stockholm, Sweden

  Britta Wahren

Policies and ethics